The arrangements secure the first-line supply contract for 4.5 years, with sales in the first full year of operations of approximately $700-800 million.
Impact on earnings Initial work and costs will be required to transition in the volume associated with the MC/CW agreement.
This will delay the timing of some of the Project Pivot savings and is likely to impact FY20 EBITDA guidance.
Shares in Sigma Healthcare (ASX:SIG) are trading 12.78 per cent higher at $0.75.